JNJ-1887 is under clinical development by Johnson & Johnson and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect JNJ-1887’s likelihood of approval (LoA) and phase transition for Wet (Neovascular / Exudative) Macular Degeneration took place on 04 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their JNJ-1887 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
JNJ-1887 (HMR-59) is under development for the treatment of wet age-related macular degeneration (AMD). The therapeutic candidate is administered through intravitreal route. It is an anti-complement gene-based therapy that utilizes adeno-associated virus vector serotype 2 (AAV2). It works by increasing the production of sCD59 by ocular cells. It was also under development for geographic atrophy (advanced form of dry age-related macular degeneration).
Johnson & Johnson overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
Quick View JNJ-1887 LOA Data
|Highest Development Stage|